Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Tonix Pharmaceuticals announced a second commercial payer agreement with a leading GPO effective June 1, 2026, providing coverage for TONMYA® to approximately 17 million additional U.S. commercial lives. Combined with the first agreement announced in May 2026, TONMYA now has commercial coverage for approximately 52 million U.S. lives (29% of total commercial lives). TONMYA is the first new fibromyalgia medicine approved by the FDA in over 15 years and is also available under Medicaid in most states covering approximately 75 million lives.